Literature DB >> 21998292

The role of CYP3A4 mRNA transcript with shortened 3'-untranslated region in hepatocyte differentiation, liver development, and response to drug induction.

Dan Li1, Roger Gaedigk, Steven N Hart, J Steven Leeder, Xiao-bo Zhong.   

Abstract

Cytochrome P450 3A4 (CYP3A4) metabolizes more than 50% of prescribed drugs. The expression of CYP3A4 changes during liver development and may be affected by the administration of some drugs. Alternative mRNA transcripts occur in more than 90% of human genes and are frequently observed in cells responding to developmental and environmental signals. Different mRNA transcripts may encode functionally distinct proteins or contribute to variability of mRNA stability or protein translation efficiency. The purpose of this study was to examine expression of alternative CYP3A4 mRNA transcripts in hepatocytes in response to developmental signals and drugs. cDNA cloning and RNA sequencing (RNA-Seq) were used to identify CYP3A4 mRNA transcripts. Three transcripts were found in HepaRG cells and liver tissues: one represented a canonical mRNA with full-length 3'-untranslated region (UTR), one had a shorter 3'-UTR, and one contained partial intron-6 retention. The alternative mRNA transcripts were validated by either rapid amplification of cDNA 3'-end or endpoint polymerase chain reaction (PCR). Quantification of the transcripts by RNA-Seq and real time quantitative PCR revealed that the CYP3A4 transcript with shorter 3'-UTR was preferentially expressed in developed livers, differentiated hepatocytes, and in rifampicin- and phenobarbital-induced hepatocytes. The CYP3A4 transcript with shorter 3'-UTR was more stable and produced more protein compared with the CYP3A4 transcript with canonical 3'-UTR. We conclude that the 3'-end processing of CYP3A4 contributes to the quantitative regulation of CYP3A4 gene expression through alternative polyadenylation, which may serve as a regulatory mechanism explaining changes of CYP3A4 expression and activity during hepatocyte differentiation and liver development and in response to drug induction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21998292      PMCID: PMC3250109          DOI: 10.1124/mol.111.074393

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  37 in total

1.  Patterns of variant polyadenylation signal usage in human genes.

Authors:  E Beaudoing; S Freier; J R Wyatt; J M Claverie; D Gautheret
Journal:  Genome Res       Date:  2000-07       Impact factor: 9.043

Review 2.  Genetic contribution to variable human CYP3A-mediated metabolism.

Authors:  Jatinder K Lamba; Yvonne S Lin; Erin G Schuetz; Kenneth E Thummel
Journal:  Adv Drug Deliv Rev       Date:  2002-11-18       Impact factor: 15.470

3.  Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase.

Authors:  P H Beaune; D R Umbenhauer; R W Bork; R S Lloyd; F P Guengerich
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

4.  Infection of a human hepatoma cell line by hepatitis B virus.

Authors:  Philippe Gripon; Sylvie Rumin; Stephan Urban; Jacques Le Seyec; Denise Glaise; Isabelle Cannie; Claire Guyomard; Josette Lucas; Christian Trepo; Christiane Guguen-Guillouzo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-13       Impact factor: 11.205

5.  A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.

Authors:  Steven N Hart; Ye Li; Kaori Nakamoto; Eva-anne Subileau; David Steen; Xiao-bo Zhong
Journal:  Drug Metab Dispos       Date:  2010-03-12       Impact factor: 3.922

6.  Developmental expression of the major human hepatic CYP3A enzymes.

Authors:  Jeffrey C Stevens; Ronald N Hines; Chungang Gu; Sevasti B Koukouritaki; Jason R Manro; Peter J Tandler; Matthew J Zaya
Journal:  J Pharmacol Exp Ther       Date:  2003-09-15       Impact factor: 4.030

7.  Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver.

Authors:  D T Molowa; E G Schuetz; S A Wrighton; P B Watkins; P Kremers; G Mendez-Picon; G A Parker; P S Guzelian
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

Review 8.  Alternative splicing: multiple control mechanisms and involvement in human disease.

Authors:  Javier F Cáceres; Alberto R Kornblihtt
Journal:  Trends Genet       Date:  2002-04       Impact factor: 11.639

9.  Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation.

Authors:  Cole Trapnell; Brian A Williams; Geo Pertea; Ali Mortazavi; Gordon Kwan; Marijke J van Baren; Steven L Salzberg; Barbara J Wold; Lior Pachter
Journal:  Nat Biotechnol       Date:  2010-05-02       Impact factor: 54.908

10.  Sequence determinants in human polyadenylation site selection.

Authors:  Matthieu Legendre; Daniel Gautheret
Journal:  BMC Genomics       Date:  2003-02-25       Impact factor: 3.969

View more
  6 in total

1.  CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing.

Authors:  Danxin Wang; Wolfgang Sadee
Journal:  Pharmacogenet Genomics       Date:  2016-01       Impact factor: 2.089

2.  RNA sequencing reveals dynamic changes of mRNA abundance of cytochromes P450 and their alternative transcripts during mouse liver development.

Authors:  Lai Peng; Byunggil Yoo; Sumedha S Gunewardena; Hong Lu; Curtis D Klaassen; Xiao-Bo Zhong
Journal:  Drug Metab Dispos       Date:  2012-03-20       Impact factor: 3.922

3.  Expression dynamics of pregnane X receptor-controlled genes in 3D primary human hepatocyte spheroids.

Authors:  Tomas Smutny; Veronika Bernhauerova; Lucie Smutna; Jurjen Duintjer Tebbens; Petr Pavek
Journal:  Arch Toxicol       Date:  2021-10-23       Impact factor: 5.153

4.  Alternative Splicing of the SLCO1B1 Gene: An Exploratory Analysis of Isoform Diversity in Pediatric Liver.

Authors:  Bianca D van Groen; Chengpeng Bi; Roger Gaedigk; Vincent S Staggs; Dick Tibboel; Saskia N de Wildt; J Steven Leeder
Journal:  Clin Transl Sci       Date:  2020-01-09       Impact factor: 4.689

5.  Genome-wide binding and transcriptome analysis of human farnesoid X receptor in primary human hepatocytes.

Authors:  Le Zhan; Hui-Xin Liu; Yaping Fang; Bo Kong; Yuqi He; Xiao-Bo Zhong; Jianwen Fang; Yu-Jui Yvonne Wan; Grace L Guo
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

6.  RNA-Seq analysis implicates detoxification pathways in ovine mycotoxin resistance.

Authors:  Jinbi Zhang; Zengxiang Pan; Stephanie Moloney; Allan Sheppard
Journal:  PLoS One       Date:  2014-06-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.